002864

22.000.36%

Panlong Pharmaceutical: PLJT-001 Loxoprofen Sodium Gel Patch has received the acceptance notice for domestic drug production registration and marketing license

LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the Zhitong Finance APP, Panlong Pharmaceutical (002864.SZ) announced that its research product, Loxoprofen Sodium Gel Patch, has received the "Acceptance Notice" for the generic drug marketing authorization application issued by the National Medical Products Administration (referred to as "NMPA").

Loxoprofen Sodium Gel Patch (PLJT-001) is a gel patch used to treat osteoarthritis, muscle pain, and swelling or pain after injuries. The active ingredient in PLJT-001 is Loxoprofen Sodium, a non-steroidal anti-inflammatory drug (NSAID) of the phenylpropionic acid class, which has significant anti-inflammatory and analgesic effects, particularly strong analgesic effects. Its mechanism of action involves the inhibition of prostaglandin synthesis, with the action point being cyclooxygenase. Loxoprofen Sodium is a prodrug that, after transdermal absorption, is converted into the active metabolite trans-OH to exert its effects. This gel patch has low irritant allergenicity, strong adhesion that is not easily detached, a lightweight formulation with good skin extensibility, and can be applied to active joints without affecting daily activities, significantly enhancing medication comfort and convenience

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.